Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma.

CONCLUSIONS: Metastases burden, LDH levels, and RLC are independent baseline characteristics associated with outcome in patients with melanoma receiving anti-PD-1. Further investigations are needed to clarify if evaluation of these parameters can translate into clinical strategy and apply to patient selection. PMID: 31446882 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research